Drugs / Vorapaxar
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Zontivity | — | 2017-06-23 | europa.eu ↗ |
| Approved | EU (EMA) | Zontivity | — | 2015-01-19 | europa.eu ↗ |
| Approved | US (FDA) | ZONTIVITY | — | 2014-05-08 | fda.gov ↗ |
Trials 11 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02475837 Comparator | Aug 2015 → Oct 2017 | cardiovascular disorder | Ken Mahaffey | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02975583 Comparator | Oct 2017 → Jan 2018 | peripheral arterial disease | Vanderbilt University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02660866 Comparator | Jul 2016 → Jul 2019 | peripheral arterial disease | North Texas Veterans Healthcare System | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vorapaxar | “Vorapaxar is a protease-activated receptor (PAR)-1 inhibitor, which exerts potent inhibition of thrombin-mediated platelet aggregation.” NCT02548650 ↗ |
| Known as | MK-5348 | “the efficacy and safety of vorapaxar (SCH 530348; MK-5348) were assessed by baseline risk among patients with previous MI without prior stroke or transient ischemic attack for...” PMID 27440003 ↗ Jul 2016 |
| Known as | SCH 530348 | “the efficacy and safety of vorapaxar (SCH 530348; MK-5348) were assessed by baseline risk among patients with previous MI without prior stroke or transient ischemic attack for...” PMID 27440003 ↗ Jul 20163“Vorapaxar, formerly SCH 530348, is a novel, orally active, potent thrombin receptor inhibitor selective for the protease-activated receptor-1 (PAR-1).” PMID 20947374 ↗ Oct 2010 “Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)” NCT00617123 ↗ |
| Known as | VORAPAXAR SULFATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL493982 ↗ |
| Known as | Zontivity | “Drug: Vorapaxar 2.08 mg orally daily for a year Other name: Zontivity” NCT02975583 ↗ |
| Action | Inhibit | “an oral platelet protease-activated receptor-1 antagonist” PMID 19286091 ↗ Mar 20091“Proteinase-activated receptor 1 antagonist” CHEMBL493982 ↗ |
| Modality | Small molecule | — CHEMBL493982 ↗ |
| Route | Oral | “Those in the SCH 530348 group who subsequently underwent PCI (primary PCI cohort) continued taking an oral maintenance dose” PMID 19286091 ↗ Mar 2009 |
| Target | F2R | “Proteinase-activated receptor 1 antagonist” CHEMBL493982 ↗ |